Combined CDK4/6 and pan-mTOR inhibition is synergistic against intrahepatic cholangiocarcinoma
- Song X.
- Liu X.
- Wang H.
- Wang J.
- Qiao Y.
- Cigliano A.
- Utpatel K.
- Ribback S.
- Pilo M. G.
- Serra M.
- Gordan J. D.
- Che L.
- Zhang S.
- Cossu A.
- Porcu A.
- Pascale R. M.
- Dombrowski F.
- Hu H.
- Calvisi D. F.
- Evert M.
- Chen X.
Publication date
January 2019
DOIAbstract
Intrahepatic cholangiocarcinoma (ICC) is an aggressive cancer type, lacking effective therapies and associated with a dismal prognosis. Palbociclib is a selective CDK4/6 inhibitor, which has been shown to suppress cell proliferation in many experimental cancer models. Recently, we demonstrated that pan-mTOR inhibitors, such as MLN0128, effectively induce apoptosis, although have limited efficacy in restraining proliferation of ICC cells. Here, we tested the hypothesis that palbociclib, due to its antproliferative properties in many cancer types, might synergize with MLN0128 to impair ICC growth
Add to ORKG